華綠生物(300970.SZ):擬參與設立南京菌生萬物生物科技股份有限公司
格隆匯8月18日丨華綠生物(300970.SZ)公佈,公司與合肥和晨生物科技有限公司、南京華菌投資管理合夥企業簽署《合資協議》,各方同意共同出資設立南京菌生萬物生物科技股份有限公司。合資公司註冊資本為500萬元人民幣,其中公司出資225萬元,持有合資公司45%股權;和晨生物出資175萬元,持有合資公司35%股權;南京華菌出資100萬元,持有合資公司20%股權。打造食用菌生物技術總部經濟項目,面向食用菌合成生物學研發和食用菌深加工及菌廢綜合利用研發,打造以“食用菌資源綜合利用+合成生物學”雙引擎為驅動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.